New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 15, 2018 - The FDA announced the approval of Retacrit (epoetin alfa-epbx), Hospira/Pfizer’s biosimilar to Amgen’s Epogen® (epoetin alfa) and Janssen’s Procrit® (epoetin alfa).
Download PDF
Return to publications
